Summary
As the FDA and HHS rein in direct-to-consumer drug advertising, new compliance rules and AI-driven monitoring could require some pharma companies to rethink their marketing approach.
Source: Techtarget.com
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
